Clinical and radiographic differentiation of lung nodules caused by mycobacteria and lung cancer: a case–control study

BMC Infectious Diseases

Michael S. Glickman¹  Elyn Riedel²  Cesar J. Figueroa³ 

[1] Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10065, NY, USA;Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10065, NY, USA;Department of Medicine, Infectious Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York 10065, NY, USA

关键词: Lung Neoplasms;    Positron-Emission Tomography;    Pulmonary Nodule;    Mycobacterial Lung Nodules;    Pulmonary Mycobacteria;   

Others  :  1232696
DOI  :  10.1186/s12879-015-1185-4

 received in 2015-04-16, accepted in 2015-10-06,  发布年份 2015

【 摘 要 】

Background

Lung nodules caused by mycobacteria can resemble lung cancer on chest imaging. The advent of lung cancer screening with low-dose Computed Tomography is accompanied by high false-positive rates, making it necessary to establish criteria to differentiate malignant from benign nodules.

Methods

We conducted a retrospective case–control study of 52 patients with mycobacterial lung nodules and 139 patients with lung cancer, diagnosed between 2010 and 2012. We compared clinical and radiographic characteristics to identify predictors of disease by univariate and multivariate analysis. The discriminatory power of maximum Standardized Uptake Values from Positron-Emission-Tomography was also evaluated.

Results

Several variables were correlated with a diagnosis of mycobacterial infection or lung cancer on univariate analysis. Such variable include smoking status and history, lesion size and imaging evidence of tree-in-bud opacities, lymphadenopathy or emphysema on computed tomography. Upon author consensus, the most clinically-relevant variables were selected to undergo multivariate analysis. A history of current or former smoking [OR 4.4 (95 % CI 1.2–15.6) and 2.7 (95 % CI 1.1–6.8), respectively P = 0.04] was correlated with diagnoses of lung cancer. Contrarily, the presence of tree-in-bud opacities was less likely to be correlated with a diagnosis of malignancy [OR 0.04 (95 % CI 0.0–1.0), P = 0.05]. Additionally, higher maximum standardized uptake values from positron emission tomography were associated with malignancy on multivariate analysis [OR 1.1 (95 % CI 1.0–1.2), P = 0.04]; but the accuracy of the values in differentiating between diseases was only 0.67 as measured by the area under the curve. Lesion size was not independently associated with diagnosis [OR 0.5 (95 % CI 0.2–1.2), (P = 0.12)].

Conclusions

Establishing the likelihood of malignancy for lung nodules based on isolated clinical or radiographic criteria is difficult. Using the variables found in this study may allow clinicians to stratify patients into groups of high and low risk for malignancy, and therefore establish efficient diagnostic strategies.

【 授权许可】

   
2015 Figueroa et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM et al.. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409.
• [2]National Lung Screening Trial Research T, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS et al.. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368(21):1980-1991.
• [3]Moyer VA. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014; 160:330-338.
• [4]Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e78S-92S.
• [5]Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R et al.. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012; 144(1):33-38.
• [6]Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF et al.. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013; 369(10):920-931.
• [7]McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M et al.. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013; 369(10):910-919.
• [8]de Koning HJ, Meza R, Plevritis SK, Ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J et al.. Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160:311-320.
• [9]Erasmus JJ, McAdams HP, Farrell MA, Patz EF. Pulmonary nontuberculous mycobacterial infection: radiologic manifestations. Radiographics. 1999; 19(6):1487-1505.
• [10]Gribetz AR, Damsker B, Bottone EJ, Kirschner PA, Teirstein AS. Solitary pulmonary nodules due to nontuberculous mycobacterial infection. Am J Med. 1981; 70(1):39-43.
• [11]Hahm CR, Park HY, Jeon K, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Koh WJ. Solitary pulmonary nodules caused by Mycobacterium tuberculosis and Mycobacterium avium complex. Lung. 2010; 188(1):25-31.
• [12]Lim J, Lyu J, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Lee H, Shim TS. Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules. Int J Tuberc Lung Dis. 2010; 14(12):1635-1640.
• [13]Miller WT. Spectrum of pulmonary nontuberculous mycobacterial infection. Radiology. 1994; 191(2):343-350.
• [14]Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest. 2003; 124(3):893-901.
• [15]Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. AJR Am J Roentgenol. 2004; 182(4):983-989.
• [16]Lillington GA, Caskey CI. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med. 1993; 14(1):111-119.
• [17]Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF et al.. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416.
• [18]Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest. 1991; 99(3):667-669.
• [19]Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M. Four cases of pulmonary Mycobacterium avium intracellulare complex presenting as a solitary pulmonary nodule and a review of other cases in Japan. Respirology. 2006; 11(3):317-321.
• [20]Yonemori K, Tateishi U, Tsuta K, Yonemori Y, Uno H, Asamura H, Kusumoto M. Solitary pulmonary granuloma caused by Mycobacterium avium-intracellulare complex. Int J Tuberc Lung Dis. 2007; 11(2):215-221.
• [21]Hutchinson L. Screening: CT screening for lung cancer: winner confirmed. Nat Rev Clin Oncol. 2013; 10(7):367.
• [22]Georgiadou SP, Sampsonas FL, Rice D, Granger JM, Swisher S, Kontoyiannis DP. Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32(1):101-105.
• [23]Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can. Respir. J. 2011; 18(1):19-24.
• [24]Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, Yang PC, Luh KT, Hsueh PR. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis. 2010; 16(2):294-296.
• [25]Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, MontesdeOca R, Shea YR, Seitz AE, Holland SM et al.. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010; 182(7):970-976.
• [26]Al-Houqani M, Jamieson F, Mehta M, Chedore P, May K, Marras TK. Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. Chest. 2012; 141(1):190-197.
• [27]Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. 2009; 36(4):632-639.
• [28]Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon YS, Dreher MR, Kastenmayer RJ, Laymon CM et al.. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother. 2012; 56(8):4391-4402.
• [29]Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother. 2009; 53(11):4879-4884.
• [30]Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006; 82(3):1016-1020.